JP2004532227A - ベータ−３アデノレセプタ作動薬として有用な２，６−置換クロマン誘導体 - Google Patents

ベータ−３アデノレセプタ作動薬として有用な２，６−置換クロマン誘導体 Download PDF

Info

Publication number
JP2004532227A
JP2004532227A JP2002583418A JP2002583418A JP2004532227A JP 2004532227 A JP2004532227 A JP 2004532227A JP 2002583418 A JP2002583418 A JP 2002583418A JP 2002583418 A JP2002583418 A JP 2002583418A JP 2004532227 A JP2004532227 A JP 2004532227A
Authority
JP
Japan
Prior art keywords
amino
methyl
dihydro
pyridinyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002583418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532227A5 (https=
Inventor
オコナー，ステイーブン・ジエイ
ラドウシユール，ゲタン・エイチ
バロツク，ウイリアム・エイチ
キヤンベル，アン−マリー
ダイ，ミアオ
ダリー，ロバート
デユマ，ジヤツク
ハトウム−モクダド，ホリア・エヌ
キレ，ウダイ
リー，ウエンデイ
リウ，シンジー
ロウエ，デレク・ビー
マグヌソン，ステイーブ・アール
シー，ニング
シエレキン，タチアナ・イー
シエン，クアンロング
スミス，ロジヤー・エイ
ワング，ミング
Original Assignee
バイエル・フアーマシユーチカルズ・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル・フアーマシユーチカルズ・コーポレーシヨン filed Critical バイエル・フアーマシユーチカルズ・コーポレーシヨン
Publication of JP2004532227A publication Critical patent/JP2004532227A/ja
Publication of JP2004532227A5 publication Critical patent/JP2004532227A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2002583418A 2001-04-23 2002-04-22 ベータ−３アデノレセプタ作動薬として有用な２，６−置換クロマン誘導体 Withdrawn JP2004532227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US32451801P 2001-09-26 2001-09-26
PCT/US2002/012940 WO2002085891A1 (en) 2001-04-23 2002-04-22 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Publications (2)

Publication Number Publication Date
JP2004532227A true JP2004532227A (ja) 2004-10-21
JP2004532227A5 JP2004532227A5 (https=) 2005-12-22

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002583418A Withdrawn JP2004532227A (ja) 2001-04-23 2002-04-22 ベータ−３アデノレセプタ作動薬として有用な２，６−置換クロマン誘導体

Country Status (9)

Country Link
US (3) US6660752B2 (https=)
EP (1) EP1389202B1 (https=)
JP (1) JP2004532227A (https=)
AR (1) AR035858A1 (https=)
DE (1) DE60201437T2 (https=)
DO (1) DOP2002000385A (https=)
ES (1) ES2230487T3 (https=)
PE (1) PE20021073A1 (https=)
WO (1) WO2002085891A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520738A (ja) * 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ９活性の阻害剤
JP2014525445A (ja) * 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2566196A1 (en) * 2004-05-05 2005-11-10 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
ES2306275T3 (es) * 2004-12-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de cromano y sus usos como ligandos dde receptores 5-ht.
CA2591810A1 (en) 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
SI1831159T1 (sl) * 2004-12-21 2010-04-30 Hoffmann La Roche Derivati tetralina in indana ter njune uporabe
RU2388748C2 (ru) * 2004-12-21 2010-05-10 Ф. Хоффманн-Ля Рош Аг Производные тетралина и индана и их применения в качестве антагонистов 5-нт
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
CA2628173A1 (en) * 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
MX2008015511A (es) * 2006-06-20 2008-12-18 Hoffmann La Roche Derivados de arilsulfonilnaftaleno y usos de los mismos.
AU2007263075A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
BRPI0713736A2 (pt) * 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
CA2895256C (en) 2013-01-09 2021-06-01 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
WO2014207648A1 (en) * 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
CN106028817A (zh) 2013-07-08 2016-10-12 巴斯夫农业公司 包含三唑化合物和生物农药的组合物
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
EA201892682A1 (ru) 2014-06-25 2019-04-30 Басф Агро Б.В. Пестицидные композиции
US10053436B2 (en) 2014-07-08 2018-08-21 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
DK3294720T3 (da) 2015-05-08 2021-02-15 Basf Agro Bv Fremgangsmåde til fremstilling af terpinolenepoxid
EP3294700B1 (en) 2015-05-08 2020-01-29 BASF Agro B.V. A process for the preparation of limonene-4-ol
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383388B1 (en) 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
ES3056157T3 (en) 2016-03-16 2026-02-18 Basf Se Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
CA3015456C (en) 2016-03-16 2024-09-17 Basf Se USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
MX2018015764A (es) 2016-06-15 2019-08-29 Basf Agro Bv Proceso para la epoxidacion de un alqueno tetrasustituido.
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US12545649B2 (en) 2019-11-18 2026-02-10 Vanderbilt University WDR5-MYC inhibitors
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
DE3275295D1 (en) 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
ID22273A (id) 1997-01-28 1999-09-23 Merck & Co Inc TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
JP2001526282A (ja) * 1997-12-19 2001-12-18 バイエル・コーポレーシヨン β−３アドレナリン受容体作用薬として有用なカルボキシル置換クロマン誘導体
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6393316B1 (en) * 1999-05-12 2002-05-21 Medtronic, Inc. Method and apparatus for detection and treatment of cardiac arrhythmias
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520738A (ja) * 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ９活性の阻害剤
JP2014525445A (ja) * 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法

Also Published As

Publication number Publication date
US6660752B2 (en) 2003-12-09
US6919371B2 (en) 2005-07-19
EP1389202A1 (en) 2004-02-18
EP1389202B1 (en) 2004-09-29
DE60201437T2 (de) 2005-12-15
DE60201437D1 (de) 2004-11-04
US20050215594A1 (en) 2005-09-29
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
DOP2002000385A (es) 2004-01-31
ES2230487T3 (es) 2005-05-01
WO2002085891A1 (en) 2002-10-31
PE20021073A1 (es) 2002-12-12
AR035858A1 (es) 2004-07-21

Similar Documents

Publication Publication Date Title
US6660752B2 (en) 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6699860B2 (en) Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6780859B2 (en) Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
WO2003106452A2 (en) Antagonists of melanin concentrating hormone receptor
KR20130112896A (ko) Ttx-s 차단제로서의 아릴아미드 유도체
JP2017081918A (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP2007525513A (ja) 糖尿病の処置に有用なヘテロアリールアミノピラゾール誘導体
EP1054881B1 (en) Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
EP1040106B1 (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6797714B2 (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные
CZ20002257A3 (cs) Karboxysubstituované chromanové deriváty, které lze použít jako beta-3-adrenoreceptorové agonisty

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050311

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061124